Search Results

PROMIS Item Bank v1.0 - Dyspnea Severity Patient Reported Outcomes Measurement Information System Item Bank - Dyspnea Severity For patients with dyspnea LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview A bank of dyspnea items. MEASURE NAME: PROMIS Item Bank v1.0 - Dyspnea Severity VERSION: 1 NUMBER OF ITEMS: 33 PATIENT POPULATION: Dyspnea patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 4 point Likert-type scale DATA COLLECTION: Paper and electronic For permission to implement and administer the measure electronically, please visit: https://www.healthmeasures.net/implement-healthmeasures/administration-platforms ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Severity TIME FOR COMPLETION: 10-15 minutes SCORING: PROMIS Scoring Service: http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions RELATED MEASURES: FACIT-Dyspnea , PROMIS SF v1.0 – Dyspnea-Severity 10a , PROMIS SF v1.0 – Dyspnea-Severity 5b DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the PROMIS Item Bank v1.0 - Dyspnea Severity can be obtained by registering for permission. Users are not permitted to translate the PROMIS Item Bank v1.0 - Dyspnea Severity without permission from FACIT.org. Permission from FACIT.org to translate the PROMIS Item Bank v1.0 - Dyspnea Severity may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Choi, S., Victorson, D., Yount, S., Anton, S., & Cella, D. Development of a conceptual framework and calibrated item banks to measure patient reported dyspnea severity and related functional limitations. Value in Health 2011; 14: 291-306. Ruo, B., Choi, S., Baker, D., Grady, K., & Cella,D. Development and validation of a computer adaptive test measuring dyspnea in heart failure. Journal of Cardiac Failure 2010; 16(8): 659-668. doi: 10.1016/j.cardfail.2010.03.002. Victorson, D., Anton, S., Hamilton, A., Yount, S., & Cella, D. A conceptual model of the experience of dyspnea and functional limitations in COPD. Value in Health 2009; 12(6): 1018-1025. Yount, S., Choi, S., Victorson, D., Ruo, B., Ray, D., Cella, D., Anton, S., & Hamilton, A. (2011) Brief, valid measures of dyspnea and related functional limitations in chronic obstructive pulmonary disease (COPD). Value in Health 2011; 14: 307-315. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-Dyspnea Functional Assessment of Chronic Illness Therapy - Dyspnea-10 item LEARN MORE PROMIS SF v1.0 – Dyspnea Severity 10a Patient-Reported Outcomes Measurement Information System Short Form - Dyspnea Severity 10a LEARN MORE PROMIS SF v1.0 – Dyspnea Severity 5b Patient-Reported Outcomes Measurement Information System Short Form - Dyspnea Severity 5b LEARN MORE

FACIT Translation & Linguistic Validation Methodology First published in 1996 and adopted by the HealthMeasures family of measurement systems (Patient-Reported Outcomes Measurement Information System (PROMIS®); Quality of Life in Neurological Disorders (Neuro-QoL); NIH Toolbox; as well as the Critical Path Institute's PRO Consortium; the FACIT Translation and Linguistic validation methodology emphasizes a “universal” translation approach in order to achieve a single, valid translation for each language, designed to work across different countries that speak the same language. The universal approach provides several advantages to a country-specific approach that produces multiple same-language versions across different countries. These advantages include the following: (1) enables language subgroup comparison, without requiring a check on bias introduced by different translations (e.g., comparing Spanish-speaking groups in the United States to one another or to people in Spain or Latin America); (2) minimizes bias introduced by multiple, country-specific translations in a project or trial; (3) simplifies logistics and analysis of multinational clinical trials; and (4) facilitates survey administration in the case of migrating populations. In cases requiring a universal translation, the standard methodology is modified during the translation and review steps and in cognitive debriefing to include native linguists from each relevant country. This is a more rigorous version of the double-back-translation method considered superior to single translation and translation by committee (Bonomi et al., 1996). The process is summarized as follows: For each target language, the source is translated by two independent professional translators. Next, a third independent translator reconciles the two forward translations by choosing the better of the two forward translations and resolving discrepancies between them. This reconciled version is then back-translated blindly by a native English-speaking translator fluent in the target language. The developer reviews the back-translation for discrepancies from the source version and to assess equivalence with the source. Subsequently, an additional independent review/finalization is performed by a native speaking linguist and harmonization with other existing translations is conducted by the developer in conjunction with the linguist. Finally, the target-language version is pretested with patients in the country in which the language is spoken. If any items are found to be problematic by patients, their feedback allows for modifications in the translations and for indications of changes that may later be made to the original source document, an example of the decentering process (Lent, Hahn, Eremenco, Webster, & Cella, 1999). The Universal Approach: For languages native to multiple countries, representatives from each country work together in conjunction with FACIT to develop one version of an item valid for use in every country a language is spoken, rather than country-specific versions. Learn more about FACITtrans’ services All items in the FACIT Measurement System undergo this methodology and FACITtrans is the only vendor authorized to translate and linguistically validate FACIT items. Permission to translate any FACIT item or measure should be obtained prior to undertaking this methodology. Contact us for more details. If permission has not been obtained, the item or scale will not be recognized as part of the FACIT measurement system.

Download this measure in English. BACK FAMS English Downloads Download PDF Download DOC

Clinical outcomes assessment (COA) translation, linguistic validation and cross-cultural assessment with over 25 years expertise providing cutting edge services and consultation to health outcomes researchers in the pharmaceutical industry and in federally-funded initiatives. Translation & Linguistic Validation FOR THE LIFE SCIENCE AND HEALTH STATUS RESEARCH COMMUNITIES We are an industry pioneer in clinical outcome assessment (COA) translation, linguistic validation and cross-cultural assessment with over 25 years expertise providing cutting edge services and consultation to health outcomes researchers in the pharmaceutical industry and in federally-funded initiatives. While our work began with the renowned FACIT Measurement System, it has broadened to include a variety of Clinical Outcome Assessments (COAs) providing valuable services over a broad range of disease areas. We offer a wide range of services for your studies: Linguistic Validation Translatability Assessment Translation of Consent Forms and Protocols Interview Transcription and Translation eCOA Adaptation and Migration We look forward to serving your study needs. Contact us to get started! Frequently asked questions Expertise FAQ Clinical Outcome Assessments (COA) Translation Most outcomes measures have been developed and validated in English. In order to ensure that data collected in multinational clinical trials can be pooled for analysis and ultimately submitted for a label claim, translated versions of COA's must be as conceptually and culturally equivalent as possible. To achieve this equivalence, a rigorous translation methodology with attendant focus on quality and cultural appropriateness is imperative. Through our industry-wide recognized translation approach, we deliver on the promise that our translations are linguistically and culturally appropriate for each target population, and that patients across the globe understand translated items as intended by the English source instrument. https://static.wixstatic.com/media/undefined Linguistic Validation Patients live with their disease, treatment or conditions. As such, patients themselves provide the most informative, useful perspective on a questionnaire's (COA’s) content. FACITtrans’ full COA translation methodology specifically requires interviewing patients with the translated questionnaire and asking them questions about the items in order to fully capture the target-language patient’s voice and experience. This process, called “cognitive interviewing”, helps ensure the final translated versions are as conceptually and culturally equivalent as possible. These steps seek to affirm the linguistic validity of the translated measure and ultimately strengthen our clients’ ability to understand the multinational patient perspective and obtain a label claim from internationally-collected clinical trial data. At FACITtrans, we believe capturing the patient voice is imperative. As highlighted on our History page,(javascript:void(0)) our team was part of the original publication of these now widely-accepted translation approaches. For over 20 years our mission has been Providing A Voice for Patients Worldwide. We deliver on this promise to patients and our clients every day. https://static.wixstatic.com/media/undefined eCOA Translation, Adaptation, Migration and Screenshot Proofreading Electronic Clinical Outcome Assessment (eCOA) is a way of capturing data electronically in clinical trials. Many measures were developed for paper administration. When adapted for electronic assessment, often there must be some adjustments to the measure’s instructions or layout. FACITtrans’ eCOA expertise includes: • Adapted over 90% of FACIT scales into as many as 70 languages • Adapted over 15 non-FACIT instruments into as many as 30 languages • Currently supporting >15 pharma clients & eCOA vendors FACITtrans provides these services: • Instruction adaptation for clear patient comprehension • Adapt language to fit context of device • Multilingual migration to XML, JSON and CSV formats • Screenshot proofing across variety of electronic platforms https://static.wixstatic.com/media/undefined • Learn about FACTtrans’ expertise with eCOA’s(https://www.facit.org/expertise) Interview Transcription and Translation Conducting interviews in other countries, but need transcripts of the interview in English? We have years of experience transcribing interviews, and translating the interviews into English for you. Quality checks are scheduled at each step of the process. Translation of Consent forms, Diaries, Event Logs and Protocols As longtime members of an academic research community (it's where we got our start!) we are well versed in the administrative and legal requirements of clinical trial research. Standardized documentation such as diaries, event logs, or legal/administrative documentation like consent forms or protocols require simpler translation methods but with rigorous quality and semantic monitoring. Translatability Assessment and Concept Definition COA measures are most-often developed in English, and certain concepts may not translate easily or prove to have limited or no conceptual equivalence in other cultures. Translatability Assessment refers to the proactive process of identifying such issues as early in the instrument development process as possible. Concept definition, also referred to as concept elaboration, goes hand in hand with this process and serves to define terminology and intended meaning of items providing acceptable translation alternatives, unacceptable translation alternatives, and offering solutions for specific translation issues within linguistic families. Engagement with instrument developers is crucial at these key stages to ensure the intended meaning of each item is conveyed to produce translated items that say what they mean and mean what they say. FAQ Services Quality in and across projects, no rework. LEARN MORE Publications Active contributors in the fields of translation and COAs. LEARN MORE Affiliations Sponsor and contributor for 25+ years, ISOQOL, ISPOR, ATA, and more. LEARN MORE Label Claims Our translations in label claims. LEARN MORE FACITtrans is ISO 9001:2015 and ISO 17100:2015 certified.

FACT-RNT Functional Assessment of Cancer Therapy – Radionuclide Therapy For patients receiving radionuclide therapy LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) is a standardized measure to monitor relevant symptoms and toxicities among prostate cancer patients in RNT trials and clinical settings. It was developed first by identifying relevant symptoms and toxicities by reviewing published trials and interviewing prostate cancer patients receiving radionuclide therapy (n=529), caregivers (n=514), and clinicians (n=511), then by selecting items for inclusion. The item list was refined with input from experts in RNTs and patient reported outcomes measures. MEASURE NAME: Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) VERSION: 1 NUMBER OF ITEMS: 15 PATIENT POPULATION: Patients receiving radionuclide therapy (RNT) for prostate cancer aged 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: RNT TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, total score possible. RELATED MEASURES: FACT-P , NFPSI-17 , FPSI DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-RNT can be obtained by registering for permission. Users are not permitted to translate the FACT-RNT without permission from FACIT.org. Permission from FACIT.org to translate the FACT-RNT may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Gudenkauf LM, Chavez M, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. J Nucl Med. 2023 Jan 12:jnumed.122.264946. doi: 10.2967/jnumed.122.264946. Epub ahead of print. PMID: 36635088. LICENSE THIS MEASURE Related Measures Related Measures FACT-P Functional Assessment of Cancer Therapy – Prostate LEARN MORE NFPSI-17 NCCN/FACT Prostate Cancer Symptom Index - 17 Item Version LEARN MORE FPSI FACT Prostate Cancer Symptom Index - 7 Item Version LEARN MORE

FACT-Lym Functional Assessment of Cancer Therapy – Lymphoma For patients with Lymphoma (NHL) LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Lymphoma (FACT-Lym) was developed to address health-related quality-of-life issues for NHL patients. Items for the FACT lymphoma subscale were generated from healthcare provider interviews, published literature, and content validity patient interviews. The scale was validated on a sample of 84 NHL patients, with additional measures at baseline (T1), 3–7 days (T2), and 8–12 weeks (T3). Item correlations, expert relevance ratings, and patient input on content shortened the initial 22-item lymphoma subscale to 15 items. The validation sample included 56% female, 76.2% white, 60% indolent disease, and 85% receiving treatment. Internal consistency coefficients for the subscale (.79, .85, and .84 T1–T3) and test-retest stability (.84) indicated good reliability. Correlations between the lymphoma scale and SF-36 physical (𝑟 = .62) and mental (𝑟 = .48) summary scores reflect concurrent validity. Responsiveness to ECOG performance status and treatment status exceeded established FACT subscale scores. The subscale differentiated patients’ retrospective ratings of change in each of the three groups (better; unchanged; worse), 𝑃 < 0.001. MEASURE NAME: Functional Assessment of Cancer Therapy – Lymphoma (FACT-Lym) VERSION: 4 NUMBER OF ITEMS: 42 PATIENT POPULATION: Lymphoma patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Lymphoma Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: NFLymSI-18 , FACT-Leu , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Lym can be obtained by registering for permission. Users are not permitted to translate the FACT-Lym without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Lym may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Hlubocky, F., Webster, K., Cashy, J., Beaumont, J., & Cella, D. The development and validation of a measure of health-related quality of life for non-hodgkin’s lymphoma: the functional assessment of cancer therapy—lymphoma (FACT-Lym). Lymphoma 2013; Article ID 147176. doi: 10.1155/2013/147176. Hlubocky, F., Webster, K., Beaumont, J., Cashy, J., Paul, D., Abernathy, A., Syrjala, K., Von Roenn, J., & Cella, D. A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Lymphoma Symptom Index. Leukemia & Lymphoma 2013; 54(9): 1942-1946. doi: 10.3109/10428194.2012.76297. Pettengell, R., Donatti, C., Hoskin, P., Poynton, C., Kettle, P., Hancock, B., Johnson, S., Dyer, M., Rule, S., Walker, M., & Wild, D. The impact of follicular lymphoma on health-related quality of life. Annals of Oncology 2008; 19: 570–576. doi: 10.1093/annonc/mdm543. Cheson B.D., Trask P.C., Gribben J.G., et al. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Ann Hematol. 2017;96(2):253-259. doi:10.1007/s00277-016-2878-5. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures NFLymSI-18 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index - 18 Item Version LEARN MORE FACT-Leu Functional Assessment of Cancer Therapy – Leukemia LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

FACT-P Functional Assessment of Cancer Therapy – Prostate For patients with Prostate cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Prostate (FACT-P) is a meaningful component of QOL evaluation in men undergoing therapy for prostate cancer. It was developed and tested in three independent samples: a subscale development sample (n = 43), validity sample 1 (n = 34), and validity sample 2 (n = 96). MEASURE NAME: Functional Assessment of Cancer Therapy – Prostate (FACT-P) VERSION: 4 NUMBER OF ITEMS: 39 PATIENT POPULATION: Prostate cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Prostate Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FPSI , NFPSI-17 , FACT-RNT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-P can be obtained by registering for permission. Users are not permitted to translate the FACT-P without permission from FACIT.org. Permission from FACIT.org to translate the FACT-P may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Beaumont, J., Butt, Z., Li, R., & Cella, D. Meaningful Differences and Validity for the NCCN/FACT-P Symptom Index: An analysis of the ALSYMPCA data. Cancer 2019; 125(11): 1877-1885. doi: 10.1002/cncr.31973. Beer, T., Miller, K., Tombal, B., Cella, D., DePhung, Holmstrom, S., Ivanescu, C., Skaltsa, K., & Naidoo, S. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. European Journal of Cancer 2017; 87: 21-29. doi: 10.1016/j.ejca.2017.09.035. Cella, D., Petrylak, D., Fishman, M., Teigland, C., Young, J., & Mulani, P. Role of quality of life in men with metastatic hormone-refactory prostate cancer: How does Astrsentan influence quality of life? European Urology 2006; 49: 781-789. doi: 10.1016/j.eururo.2005.12.05. Cella, D., Nichol, M., Eton, D., Nelson, J., & Mulani, P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy – Prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value in Health 2009; 12(1): 124-129. Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K.J. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument. Urology 1997; 50(6): 920-928. Orakwe, D., Tijani, K., Jeje, E., Ogunjimi, M., Rufus, W., & Alab, T. Bilateral Subcapsular Orchiectomy versus Bilateral Total Orchiectomy: Comparison of the Quality of Life Post‑Orchiectomy. Nigerian Postgraduate Medical Journal 2018; 25(1): 43-47. doi: 10.4103/npmj.npmj_169_17. Parker, C., Nilsson, s., Heinrich, D., Helle, S., O’Sullivan, J., Fosså, S., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D., Hoskin, P., Bottomley, D., James, N., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall’Oglio, M., Franzén, L., Coleman, R., Vogelzang, N., O’Bryan-Tear, C., Staudacher, K.., Garcia-Vargas, J., Shan, M., Bruland, Ø.., & Sartor, O. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. The New England Journal of Medicine 2013; 369(3): 213-223. doi: 10.1056/NEJMoa121375. Saad, F., Cella, D., Basch, E., Hadaschik, B., Mainwaring, P., Oudard, S., Graff, J., McQuarrie, K., Li, S., Hudgens, S. Lawson, J., Lopez-Gitlitz, A., Yu, M., Smith, M., & Small, E. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. The Lancet Oncology 2018; 19(10):1404-1416. doi: 10.1016/ S1470-2045(18)30567-9. Sullivan, P. Nelson, J., Mulani, P., & Slee, D. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Quality of Life Research 2006; 15: 1297–1306. doi: 10.1007/s11136-006-0003-2. Vashistha, V., Singh, B., Kaur, S., Prokop, L., & Kaushik, D. The Effects of Exercise on Fatigue, Quality of Life, and Psychological Function for Men with Prostate Cancer: Systematic Review and Meta-analyses. European Urology Focus 2016; 2(3): 284-295. doi: 10.1016/j.euf.2016.02.011. Victorson, D., Beaumont, J, Rosenbloom, S., Shevrin, D, & Cella, D. Efficient assessment of the most important symptoms in advanced prostate cancer: The NCCN/FACT-P symptom index. Psycho-Oncology 2011; 20(9): 977-983. doi: 10.1002/pon.1817. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FPSI Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 7 Item Version LEARN MORE NFPSI-17 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 17 Item Version LEARN MORE FACT-RNT Functional Assessment of Cancer Therapy – Radionuclide Therapy LEARN MORE

FACT-O Functional Assessment of Cancer Therapy – Ovarian For patients with Ovarian cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Ovarian (FACT-O) provides a reliable and valid assessment of the quality of life of women with ovarian cancer, and is appropriate as a brief quality of life assessment in clinical trials and descriptive studies. It was initially validated with 232 ovarian cancer patients attending an outpatient gynecologic oncology clinic, who completed the measure at baseline. The patients’ FACT-O scores were then compared with their performance status, disease stage, treatment status, and other factors hypothesized to be related to quality of life. Patients received a second measure either one week after baseline to assess the instrument’s test-retest reliability and/or two months after baseline to evaluate its sensitivity to change in performance status. Overall, the subscales correlated with other measures as expected; all correlations were in the hypothesized direction. Patients with advanced disease, poor performance status, and who were receiving active treatment had lower scores on physical, functional, and ovarian cancer-specific scales. The total FACT-O and emotional well-being scores were lower for patients with poor performance status and patients in active treatment. The FACT-O total and all subscale scores except emotional well-being were sensitive to decreases in performance status. MEASURE NAME: Functional Assessment of Cancer Therapy – Ovarian (FACT-O) VERSION: 4 NUMBER OF ITEMS: 39 PATIENT POPULATION: Ovarian cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Ovarian Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FOSI , NFOSI-18 , FACT-Cx DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-O can be obtained by registering for permission. Users are not permitted to translate the FACT-O without permission from FACIT.org. Permission from FACIT.org to translate the FACT-O may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Basen-Engquist, K., Bodurka-Bevers D., Fitzgerald M., Webster K., Cella D., Hu S., & Gershenson D. Reliability and Validity of the Functional Assessment of Cancer Therapy-Ovarian. The Journal of Clinical Oncology 2001; 19(6): 1809-1817. doi: 10.1200/jco.2001.19.6.1809. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FOSI Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index - 8 Item Version LEARN MORE NFOSI-18 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index - 18 Item Version LEARN MORE FACT-Cx Functional Assessment of Cancer Therapy – Cervix LEARN MORE

FACT-An Functional Assessment of Cancer Therapy – Anemia For patients with Anemia/Fatigue LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Anemia (FACT-An) contains 20 items related to symptoms and concerns of patients with anemia along with the 27-item Functional Assessment of Cancer Therapy-General (FACT-G). Thirteen of the 20 items deal with fatigue, while the remaining 7 cover other concerns related to anemia. Using semi-structured interviews with 14 anemic oncology patients and 5 oncology experts, two instruments were produced: The FACIT-Fatigue and the FACT-Anemia. These measures were then tested with a second sample of 50 cancer patients with hemoglobin levels ranging from 7 to 15.9 g/dL. The 47-item FAC7-An scores were found to be stable (test-retest r = 0.87) and internally consistent (coefficient alpha range= 0. 95-0. 96). The symptom-specific subscales also showed good stability (test-retest r range = 0.84-0.90), and the Fatigue subscale showed strong internal consistency (coefficient alpha range = 0. 93-0. 95). Internal consistency of the miscellaneous non-fatigue items was lower but acceptable (alpha range = 0.5 9-0. 70), particularly in light of their strong relationship to patient-rated performance status and hemoglobin level. Convergent and discriminant validity testing revealed a significant positive relationship with other known measures of fatigue, a significant negative relationship with vigor, and a predicted lack of relationship with social desirability. The FACT-An is useful measure of quality of life in cancer treatment, adding more focus to the problems of fatigue and anemia. MEASURE NAME: Functional Assessment of Cancer Therapy – Anemia (FACT-An) VERSION: 4 NUMBER OF ITEMS: 47 PATIENT POPULATION: Cancer patients 18 years and older with anemia RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Anemia Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACIT-Fatigue , FACIT-F , PROMIS SF v1.0 – Fatigue 13a DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-An can be obtained by registering for permission. Users are not permitted to translate the FACT-An without permission from FACIT.org. Permission from FACIT.org to translate the FACT-An may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Casadevall, N., Durieux, P., Dubois, S., Hemery, F., Lepage, E., Quarré, M., Damaj, G., Giraudier, S., Guerci, A., Laurent, G., Dombret, H., Chomienne, C., Ribrag, V., Stamatoullas, A., Marie, J., Vekhoff, A., Maloisel, F., Navarro, R., Dreyfus, F., & Fenaux, P. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004; 104(2): 321-327. doi: 10.1182/blood-2003-07-2252. Greenberg, P., Sun, Z., Miller, K., Bennett, J., Tallman, M., Dewald, G., van der Jagt, R., Houston, J., Thomas, M., Cella, D., & Rowe, J. Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114(12): 2393–2400. doi: 10.1182/blood-2009-03-211797. Mesa, R., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., Tan, A., Atherton, P., Sloan, J., Tefferi, A. The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs). An International Internet-Based Survey of 1179 MPD Patients. Cancer 2007; 109(1): 68-76. doi: 10.1002/cncr.22365. Pinchon, D., Stanworth, S., Dore ´e, C., Brunskill, S., & Norfolk, D. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. American Journal of Hematology 2009; 84(10):671-677. doi: 10.1002/ajh.21503. Spiriti. M., Latagliata, R., Niscola, P., Cortelezzi. A., Francesconi. M., Ferrari, D., Volpe, E., Clavio, M., Grossi. A., Reyes, M., Musto, P., Mitra, M., Azzarà, A., Pagnini, D., D’Arena, G., Spadano, A., Balleari, E., Pecorari, P., Capochiani, E., De Biasi, E., Perego, D., Monarca, B., Pisani, F., Scaramella, G., & Petti, M. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005; 84: 167–176. doi: 10.1007/s00277-004-0961-9. Steensma, D., Heptinstall, K., Johnson, V., Novotny, P., Sloan, J., Camoriano, J., Niblack, J., Bennett, J., & Mesa, R. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): Results of a large internet-based survey. Leukemia Research 2008; 32: 691-698. doi: 10.1016/j.leukres.2007.10.015. Trudeau, J.J., He, J., Rose, E. et al. Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes. J Patient Rep Outcomes 4, 69 (2020). doi.org/10.1186/s41687-020-00235-4. Yellen, S.B., Cella, D.F., Webster, K.A., Blendowski, C., & Kaplan, E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. Journal of Pain and Symptom Management 1997; 13(2): 63-74. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-Fatigue Functional Assessment of Chronic Illness Therapy – Fatigue Scale LEARN MORE FACIT-F Functional Assessment of Chronic Illness Therapy – Fatigue LEARN MORE PROMIS SF v1.0 – Fatigue 13a Patient-Reported Outcomes Measurement Information System Short Form - Fatigue 13a LEARN MORE

FACT-C Functional Assessment of Cancer Therapy – Colorectal For patients with Colorectal cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy - Colorectal (FACT-C) is a measure which assesses the quality-of-life of colorectal cancer patients. This self-report instrument combines specific concerns related to colorectal cancer with those that are common to all cancer patients. It has been shown to have good internal consistency, reliability and concurrent validity, as well as an ability to distinguish between groups based on functional status and extent of disease. The FACT-C has also been found to be sensitive to changes in functional status and the colorectal cancer-specific items have been found to have adequate convergent and divergent validity. MEASURE NAME: Functional Assessment of Cancer Therapy – Colorectal (FACT-C) VERSION: 4 NUMBER OF ITEMS: 36 PATIENT POPULATION: Colorectal cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Colorectal Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FCSI , NFCSI-19 , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-C can be obtained by registering for permission. Users are not permitted to translate the FACT-C without permission from FACIT.org. Permission from FACIT.org to translate the FACT-C may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Chandramohan, K., Pandey, M., KR, S., Sebastian, P., & Thomas, B. Reliability of the Malayalam FACT-Colorectal and predictors of QOL in patients with colorectal carcinoma. World Journal of Psychosocial Oncology 2012; 1: 19-28. Lynch, B., Cerin, E., Owen, N., Hawkes, A., & Aitken, J. Prospective Relationships of Physical Activity With Quality of Life Among Colorectal Cancer Survivors. Journal of Clinical Oncology 2008; 26(27): 4480-4487. doi: 10.1200/JCO.2007.15.7917. Ward, W., Hahn, E., Mo, F., Hernandez, L., Tulsky, D., & Cella, D. Reliability and Validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Quality of Life Instrument. Quality of Life Research , 1999; 8(3): 181-195. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FCSI Functional Assessment of Cancer Therapy Colorectal Cancer Symptom Index - 9 Item Version LEARN MORE NFCSI-19 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Colorectal Cancer Symptom Index - 19 Item Version LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

BACK FACT-BMT Languages Arabic Bengali Bulgarian Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Farsi Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Lithuanian Malayalam Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Slovak Spanish Swedish Tamil Telugu Turkish Thai Urdu Vietnamese

PRRS Patient Roles and Responsibilities Scale For cancer patients LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Patient Roles and Responsibilities Scale (PRRS) was developed to enable a broader evaluation of the impact of cancer and cancer treatment, measuring ‘real world’ roles and responsibilities such as caring for others and financial and employment responsibilities. Version 2, modified in 2024, removes two items from the Jobs and Careers Subscale. MEASURE NAME: Patient Roles and Responsibilities Scale (PRRS) VERSION: 2 NUMBER OF ITEMS: 16 to 23 PATIENT POPULATION: Cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Responsibilities and Social Life, Family Well-being, Financial Well-Being, Jobs and Careers TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template RELATED MEASURES: CRRS , FACT-G Caregiver , FACT-G7 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the PRRS can be obtained when licensing the measure. Users are not permitted to translate the PRRS without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the PRRS. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Shilling, V., Starkings, R., Jenkins, V. et al. Development and validation of the patient roles and responsibilities scale in cancer patients. Qual Life Res 27 , 2923–2934 (2018). https://doi.org/10.1007/s11136-018-1940-2. LICENSE THIS MEASURE Related Measures Related Measures CRRS Caregiver Roles and Responsibilities Scale LEARN MORE FACT-G Caregiver Functional Assessment of Cancer Therapy – General – Caregiver Version LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy - General - 7 Item Version LEARN MORE